Technical Analysis for MRSN - Mersana Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MRSN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | Calm After Storm | Range Contraction | 0.00% |
| Sep 20 | Narrow Range Bar | Range Contraction | 0.00% |
| Sep 20 | NR7 | Range Contraction | 0.00% |
| Sep 19 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.49% |
| Sep 19 | Calm After Storm | Range Contraction | 1.49% |
| Sep 18 | MACD Bearish Centerline Cross | Bearish | 0.82% |
| Sep 18 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.82% |
| Sep 18 | Inside Day | Range Contraction | 0.82% |
| Sep 18 | Lower Bollinger Band Touch | Weakness | 0.82% |
| Sep 17 | Fell Below 20 DMA | Bearish | 10.14% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-10
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRSN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 23.96 |
| 52 Week Low | 8.76 |
| Average Volume | 206,973 |
| 200-Day Moving Average | 15.8663 |
| 50-Day Moving Average | 13.038 |
| 20-Day Moving Average | 13.442 |
| 10-Day Moving Average | 13.236 |
| Average True Range | 1.1556 |
| ADX | 23.42 |
| +DI | 11.9081 |
| -DI | 24.7854 |
| Chandelier Exit (Long, 3 ATRs ) | 12.4632 |
| Chandelier Exit (Short, 3 ATRs ) | 13.7678 |
| Upper Bollinger Band | 15.2022 |
| Lower Bollinger Band | 11.6818 |
| Percent B (%b) | 0.17 |
| BandWidth | 26.189555 |
| MACD Line | -0.245 |
| MACD Signal Line | -0.038 |
| MACD Histogram | -0.207 |
| Fundamentals | Value |
|---|---|
| Market Cap | 278.69 Million |
| Num Shares | 22.7 Million |
| EPS | -16.23 |
| Price-to-Earnings (P/E) Ratio | -0.76 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.13 | ||||
| Resistance 3 (R3) | 13.08 | 12.76 | 12.98 | ||
| Resistance 2 (R2) | 12.76 | 12.54 | 12.78 | 12.93 | |
| Resistance 1 (R1) | 12.51 | 12.40 | 12.64 | 12.56 | 12.89 |
| Pivot Point | 12.19 | 12.19 | 12.25 | 12.21 | 12.19 |
| Support 1 (S1) | 11.94 | 11.97 | 12.07 | 11.99 | 11.65 |
| Support 2 (S2) | 11.62 | 11.83 | 11.64 | 11.61 | |
| Support 3 (S3) | 11.37 | 11.62 | 11.56 | ||
| Support 4 (S4) | 11.42 |
